Related Experiment Video
Updated: Aug 5, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
HDAC2-Mediated SMAD7 Stabilisation Activates Wnt/β-Catenin Signalling to Drive DNA Damage Repair and Cisplatin
Yingying He1, Meiling Wu2, Xiaomin Xu2
1Department of Pathology, Quzhou People's Hospital, The Quzhou Affiliated Hospital, Wenzhou Medical University, Quzhou, Zhejiang, China.
Abstract:
To investigate the role of histone deacetylase 2 (HDAC2) in cisplatin resistance in ovarian cancer (OC). Cisplatin-resistant OC cell lines were employed to construct HDAC2 overexpression and knockdown models, and their effects on cell proliferation and apoptosis were examined. Chromatin immunoprecipitation, immunoprecipitation, and dual-luciferase reporter assays were performed to investigate the regulation of SMAD7 protein stability and promoter activity by HDAC2. Expression of DNA damage repair-related genes was detected by qRT-PCR. A xenograft mouse model was established for in vivo validation. HDAC2 was highly expressed in cisplatin-resistant OC cells. Overexpression of HDAC2 enhanced drug resistance and inhibited apoptosis and DNA damage, whereas knockdown of HDAC2 exhibited the opposite effects. Mechanistically, HDAC2 directly deacetylated the SMAD7 protein to prevent its degradation rather than suppressing its transcription via H3K27 deacetylation. The HDAC2/SMAD7 axis promoted drug resistance by activating the Wnt/β-catenin signalling pathway and modulating DNA damage repair-related genes. In vivo experiments confirmed that HDAC2 knockdown significantly inhibited tumour growth and enhanced the sensitivity. HDAC2 enhances cisplatin resistance in OC by deacetylating and stabilising SMAD7 protein, thereby activating the Wnt/β-catenin signalling pathway and promoting DNA damage repair.
Insights
Histone deacetylase 2 (HDAC2) promotes cisplatin resistance in ovarian cancer by stabilizing SMAD7, activating Wnt/β-catenin signaling, and enhancing DNA repair. Reducing HDAC2 can overcome this resistance.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Cisplatin resistance is a major challenge in ovarian cancer (OC) treatment.
- The role of histone deacetylase 2 (HDAC2) in mediating this resistance remains unclear.
Purpose of the Study:
- To elucidate the function of HDAC2 in cisplatin resistance in ovarian cancer.
- To investigate the molecular mechanisms by which HDAC2 influences drug resistance and DNA repair.
Main Methods:
- Utilized cisplatin-resistant OC cell lines with HDAC2 overexpression and knockdown models.
- Performed chromatin immunoprecipitation, immunoprecipitation, and dual-luciferase reporter assays.
- Analyzed gene expression via qRT-PCR and validated findings in a xenograft mouse model.
Main Results:
- HDAC2 was highly expressed in cisplatin-resistant OC cells.
- HDAC2 overexpression increased drug resistance and inhibited apoptosis and DNA damage.
- HDAC2 deacetylated and stabilized SMAD7 protein, activating Wnt/β-catenin signaling and promoting DNA damage repair.
Conclusions:
- HDAC2 enhances cisplatin resistance in ovarian cancer by stabilizing SMAD7.
- The HDAC2/SMAD7 axis activates Wnt/β-catenin signaling and modulates DNA damage repair genes.
- Targeting HDAC2 can overcome cisplatin resistance and inhibit tumor growth in OC.
Related Concept Videos
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
Canonical Wnt Signaling Pathway
Anaphase Promoting Complex
Abnormal Proliferation
The Intrinsic Apoptotic Pathway
